Knight Therapeutics (TSE:GUD) Reaches New 1-Year High - Here's What Happened

Key Points

• Knight Therapeutics (TSE:GUD) hit a new 52-week high, trading as high as C$6.59 and last at C$6.55 on Monday with a volume of 70,561 shares (prior close C$6.41).
• The company has a market capitalization of C$677.15 million and reported C$0.09 EPS and C$133.2 million in revenue for the quarter, but shows a negative P/E (-170.50) and negative net margin (-1.19%); analysts forecast roughly C$0.10 EPS for the current fiscal year.
• Business profile: Knight is a specialty and generic drug manufacturer focused on developing, in‑licensing, marketing and distributing pharmaceuticals and medical products, and it also finances life sciences companies to secure distribution rights.

Knight Therapeutics Inc. (TSE:GUD - Get Free Report) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as C$6.59 and last traded at C$6.55, with a volume of 70561 shares. The stock had previously closed at C$6.41.

Knight Therapeutics Price Performance

The company has a debt-to-equity ratio of 10.15, a quick ratio of 1.79 and a current ratio of 2.39. The firm has a market capitalization of C$677.15 million, a P/E ratio of -170.50, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.15. The business has a fifty day moving average of C$6.09 and a 200-day moving average of C$6.04.

Knight Therapeutics (TSE:GUD - Get Free Report) last announced its earnings results on Thursday, March 19th. The company reported C$0.09 earnings per share for the quarter. Knight Therapeutics had a negative return on equity of 0.70% and a negative net margin of 1.19%.The firm had revenue of C$133.20 million for the quarter. On average, sell-side analysts forecast that Knight Therapeutics Inc. will post 0.1009486 EPS for the current fiscal year.

About Knight Therapeutics

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.